8511 (8511) Fair Value & Analysis

Technology · Market cap HK$18.4M

8 8511 8511 · HK

PriceHK$0.7100

Fair ValueHK$0.3400

Upside-52.1%

Quality27/100

Watch 8511 for free — get notified when fair value or trend changes. Watch for free

Evidence: Low Range HK$0.2300 – HK$0.4300

Fair value as of: Jul 3, 2026

From 1 valuation models · updated today

Share price −21.1% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$0.7000 – HK$1.60 · fair‑value band HK$0.2300 – HK$0.4300 · the HK$0.7100 price screens above the HK$0.3400 fair value. As of Jul 3, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

8511 (8511) currently trades at HK$0.7100, while our model-based Fair Value estimate is HK$0.3400 — implying the stock looks roughly 52.1% overvalued today. We read business quality at 27/100 (below-average quality), in the Technology sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

Over the trailing twelve months, 8511 generated revenue of HK$32.3M at a net margin of -52.7%. Revenue grew 32.7% year over year. Fundamentals as of Jul 3, 2026

Key figures & financial health

Revenue (TTM) HK$32.3M

Revenue growth (YoY) +32.7%

Net margin -52.7%

Return on equity -117%

Free cash flow −HK$17.9M FY2025

Operating margin 2.7%

More key figures

EPS (TTM) HK$-0.7100

EPS growth (YoY) -13.9%

Net cash HK$223K FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

8511 reported revenue of HK$27.8M in FY2025 versus HK$40.0M in FY2021, a compound −8.6%/yr. Reported net income was −HK$27.3M in FY2025.

Revenue −8.6%/yr

FY21 HK$40.0M

FY22 HK$31.5M

FY23 HK$32.0M

FY24 HK$80.5M

FY25 HK$27.8M

Net income

FY21 −HK$3.3M

FY22 −HK$9.2M

FY23 −HK$28.4M

FY24 −HK$20.1M

FY25 −HK$27.3M

Is 8511 fairly valued? → Check now

Similar stocks

6 more Scientific & Technical Instruments stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).

Stock	Price	Fair Value	vs Fair Value
Keyence Corporation KYCCF	$457.38	$228.86	-50%
Keysight Technologies, Inc KEYS	$324.00	$92.23	-72%
Garmin Ltd GRMN	$231.72	$186.06	-20%
Chroma ATE Inc 2360	2,565 TWD	359.43 TWD	-86%
Teledyne Technologies Incorporated TDY	$602.27	$358.39	-40%
Hexagon AB HXGBF	$8.37	$5.49	-34%

Explore undervalued stocks

More undervalued Technology stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 8511 (8511) undervalued?

As of Jul 3, 2026, our model estimates a fair value of HK$0.3400 versus a price of HK$0.7100 — about −52% (overvalued). Model-based estimate, not financial advice.

What is the fair value of 8511?

Our model-based fair value for 8511 is HK$0.3400 (as of Jul 3, 2026), built from audited fundamentals. The current price is HK$0.7100.

What is the quality score of 8511?

8511 has a Quality Score of 27/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 8511 (8511)?

8511 reported trailing-twelve-month revenue of about HK$32.3M (latest available figure, as of Jul 3, 2026).

What is the net profit margin of 8511?

The net profit margin of 8511 is about -52.7%, meaning it is currently running at a net loss. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.